Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067846 · ClinicalTrials.gov registry record · NA
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction
A NA study, sponsored by University of Arkansas.
- Completed
- Registry status
- NA
- Development phase
- 85
- Enrollment target
NCT01067846 is a NA study that has completed, run by University of Arkansas. The registered enrollment target is 85 participants.
The verdict
NCT01067846, a NA study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
Study Summary
For this project, the investigators are interested in exploring a new way to extend and maintain drug abstinence in people who are addicted to crack cocaine. This study will combine a medication called D-Cycloserine (DCS) and weekly cognitive behavioral therapy (CBT) to assess whether the combination will enhance people's ability to stay clean (drug free) for longer periods of time. One of the greatest risks for drug relapse is drug craving. Oftentimes drug craving occurs when a person is confronted with stressors and reminders of past drug use behavior. DCS has been shown to enhance the learning of new information. By administering DCS prior to learning new techniques such as how to cope with drug craving and drug-use reminders, it is possible that patients can be more successful at living a drug free life for a longer period of time. In addition to exploring this model behaviorally, the investigators will explore changes that may occur in the brain before and after the therapy/medication intervention. A technique called MRI (Magnetic Resonance Imaging) will be used to identify areas of the brain that are being activated during an attention task. Areas of neural activation will be assessed at study entry, end of therapy (4-week endpoint) and one month following completion of the treatment program.
Interventions
- DRUG Placebo
- DRUG Seromycin (D-cycloserine, DCS)
- BEHAVIORAL Computerized Cognitive Behavioral Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067846
The ClinicalTrials.gov registry entry for NCT01067846 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01067846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01067846 about?
NCT01067846 is a clinical study titled "Cognitive Enhancement and Relapse Prevention in Cocaine Addiction". For this project, the investigators are interested in exploring a new way to extend and maintain drug abstinence in people who are addicted to crack cocaine. This study will combine a medication called D-Cycloserine (DCS) and weekly cognitive behavioral therapy (CBT) to assess whether the combinatio...
What is the current status of trial NCT01067846?
This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2010-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01067846?
The interventions under investigation include: Placebo (DRUG), Seromycin (D-cycloserine, DCS) (DRUG), Computerized Cognitive Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT01067846?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.